Dupilumab
Treatment for Chronic Sinusitis
Typical Dosage: 300 mg subcutaneously every other week
Effectiveness
90%
Safety Score
72%
Clinical Trials
10
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg subcutaneously every other week
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$42,000
Monitoring:$300
Side Effect Mgmt:$200
Total Annual:$42,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$50,000
Cost per Remission
$106,250
Comparison vs Maximal Medical Therapy
Cost Difference
+$40,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$990
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$600/year
Time Cost
$240/year
Travel + wait time
Insurance Admin Cost
$150/year
Prior auth, claims
Rx Price
$42,000/year
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWDupilumab Outcomes
for Chronic Sinusitis
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+40%
Common Side Effects
Injection site reactions
+15%
Conjunctivitis
+10%
Oral herpes
+3%
Sources:
Active Clinical Trials
4 active trials recruiting for Dupilumab in Chronic Sinusitis
Dupixent Study for Alternate Administration
NCT06750471ACTIVE NOT RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Tacoma, United States
Started: Oct 14, 2021
BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry
NCT06501807RECRUITINGNA
900 participants
INTERVENTIONAL
Lille, France +1 more
Started: Jul 11, 2024
Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
NCT04430179ACTIVE NOT RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Tampa, United States
Started: Dec 17, 2020
Biologics in Chronic Rhinosinusitis With Nasal Polyposis
NCT06824649RECRUITINGPHASE4
504 participants
INTERVENTIONAL
Portland, United States +1 more
Started: Jun 3, 2026
Completed Clinical Trials
3 completed trials for Dupilumab in Chronic Sinusitis
Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
NCT04362501COMPLETEDPHASE2
33 participants
INTERVENTIONAL
Baltimore, United States
Started: Oct 15, 2020
Dupilumab in CRSsNP
NCT04678856COMPLETEDPHASE2
71 participants
INTERVENTIONAL
Roseville, United States +57 more
Started: Dec 2, 2020
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
NCT01920893COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Rolling Hills Estates, United States +13 more
Started: Aug 1, 2013